BiotechTube

rLP2086 + MCV4 + Tdap + MCV4 + Tdap + saline + rLP2086 + saline

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vaccines

Conditions

Vaccines, Meningococcal Vaccines

Trial Timeline

Sep 28, 2011 → May 8, 2014

NCT ID
NCT01461980

About rLP2086 + MCV4 + Tdap + MCV4 + Tdap + saline + rLP2086 + saline

rLP2086 + MCV4 + Tdap + MCV4 + Tdap + saline + rLP2086 + saline is a phase 2 stage product being developed by Pfizer for Vaccines. The current trial status is completed. This product is registered under clinical trial identifier NCT01461980. Target conditions include Vaccines, Meningococcal Vaccines.

What happened to similar drugs?

10 of 20 similar drugs in Vaccines were approved

Approved (10) Terminated (0) Active (10)
✅Vaxelis™MerckApproved
✅21-valent pneumococcal conjugate vaccineMerckApproved
✅Gardasil-9MerckApproved
✅Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinantMerckApproved
✅pneumococcus conjugate vaccine 7 valent to reduce carriagePfizerApproved
✅13vPnCPfizerApproved
✅pneumococcus conjugate vaccinePfizerApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01461980Phase 2Completed

Competing Products

20 competing products in Vaccines

See all competitors
ProductCompanyStageHype Score
Vaxelis™MerckApproved
43
21-valent pneumococcal conjugate vaccineMerckApproved
50
Gardasil-9MerckApproved
39
Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinantMerckApproved
50
13-valent pneumococcal conjugate vaccine + 7-valent pneumococcal conjugate vaccinePfizerPhase 3
40
13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccinePfizerPhase 3
40
13vPnC + 23vPSPfizerPhase 3
40
13-valent Pneumococcal Conjugate VaccinePfizerPhase 3
40
pneumococcus conjugate vaccine 7 valent to reduce carriagePfizerApproved
43
13-valent Pneumococcal Conjugate Vaccine + 7vPnCPfizerPhase 3
40
13-valent Pneumococcal Conjugate Vaccine + 7vPnC + Pediacel + NeisVac-C + MenitorixPfizerPhase 3
40
13 valent pneumococcal conjugate vaccine + 7vPnc pneumococcal conjugate vaccinePfizerPhase 3
40
13vPnCPfizerApproved
43
13-valent pneumococcal conjugate vaccine + 7-valent pneumococcal conjugate vaccine + PentavacPfizerPhase 3
40
pneumococcus conjugate vaccinePfizerApproved
43
13 valent Pneumococcal Conjugate Vaccine + 13 valent Pneumococcal Conjugate Vaccine + 13 valent Pneumococcal Conjugate Vaccine + 23-valent Pneumococcal Polysaccharide Vaccine + 23-valent Pneumococcal Polysaccharide VaccinePfizerPhase 3
40
Prevenar + Infanrix hexaPfizerApproved
43
13-valent Pneumococcal Conjugate VaccinePfizerPhase 2
35
13vPnCPfizerApproved
43
13 valent pneumococcal conjugate vaccine with Polysorbate 80 + 13 valent pneumococcal conjugate vaccine without Polysorbate 80PfizerPhase 3
40